Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular edema (DME) (see B11).
Alimera has rights from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which dropped $0.39 (19%) to $1.70 on Wednesday. In Australia, the stock fell A$0.35 (17%) to A$1.75.
For the week, Alimera lost $0.42 (16%) to $2.28. pSivida was off $0.27 (13%) to $1.80 on NASDAQ and A$0.42 (19%) to A$1.80 in Australia.
BG Medicine Inc. (NASDAQ:BGMD) was off $0.37 to $6.24 last week after withdrawing a 510(k) application to FDA for the company's CardioSCORE diagnostic to identify patients at high risk for near-term major cardiovascular events. BG made the decision after determining it would not be able to submit the additional information FDA requested by Aug. 15. The company did